---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-040251"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:12:03.971510+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# InfuSystem releases updated 2024 outlook: revenue ~$134.2M, Adj. EBITDA ~$26.5M

## Summary
- 2024 estimated net revenue of $134.2M (+6.7% YoY); Adj. EBITDA $26.5M (high-teens margin).
- Recent distribution agreements: Smith+Nephew RENASYS EDGE NPWT system; exclusive U.S. ChemoMouthpiece with Sanara MedTech.
- Patient Services revenue $77.3M (TTM 6/30/24); Device Solutions $52.1M; gross margins 64.9% and 29.4%.
- Net leverage 1.53x; $40.5M total liquidity; $20M share repurchase program authorized.
- Five consecutive years of record revenue; 12% revenue CAGR 2019-2023.

## SEC filing metadata
- accession: 0001628280-24-040251
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828024040251/0001628280-24-040251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828024040251/infu-20240912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-040251
- JSON: https://secwatch.observer/filing/0001628280-24-040251.json
- Plain text: https://secwatch.observer/filing/0001628280-24-040251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.